Cargando…

Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study

BACKGROUND: ExPEC10V is a bioconjugate vaccine containing O-antigen polysaccharides of 10 extraintestinal pathogenic Escherichia coli (ExPEC) serotypes. This phase 1/2a study (NCT03819049) assessed the safety, reactogenicity, and immunogenicity of ExPEC10V (VAC52416) to prevent invasive E coli disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fierro, Carlos A, Sarnecki, Michal, Doua, Joachim, Spiessens, Bart, Go, Oscar, Davies, Todd A, van den Dobbelsteen, Germie, Poolman, Jan, Abbanat, Darren, Haazen, Wouter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442062/ https://www.ncbi.nlm.nih.gov/pubmed/37608916 http://dx.doi.org/10.1093/ofid/ofad417

Ejemplares similares

2712. Safety and Immunogenicity of two Doses of ExPEC4V Vaccine Against Extraintestinal Pathogenic Escherichia coli Disease in Healthy Adult Participants
por: B Smith, William, et al.
Publicado: (2019)

Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants
por: Inoue, Megumi, et al.
Publicado: (2018)

235. Tracking Invasive Extraintestinal Pathogenic Escherichia coli Disease in Older Adults in a Community-Based Clinical Trial Setting
por: Doua, Joachim, et al.
Publicado: (2022)

2465. O-serotype Distribution of Escherichia coli Causing Invasive Disease in Tertiary Care Hospital Patients
por: Geurtsen, Jeroen, et al.
Publicado: (2023)

Identification of Risk Factors for Invasive Extraintestinal Pathogenic Escherichia coli (ExPEC) Disease
por: Clarke, Erik, et al.
Publicado: (2021)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Salivary Immune Responses to the 7-Valent Pneumococcal Conjugate Vaccine in the First 2 Years of Life
por: Rodenburg, Gerwin D., et al.
Publicado: (2012)

Enhanced Uptake and Phototoxicity of C(60)@albumin Hybrids by Folate Bioconjugation
por: Cantelli, Andrea, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial
por: Temple, Beth, et al.
Publicado: (2019)

An observational study of the reactogenicity and immunogenicity of 13-valent pneumococcal conjugate vaccine in women of childbearing age in Papua New Guinea
por: Javati, Sarah, et al.
Publicado: (2020)

Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field
por: Poolman, Jan T., et al.
Publicado: (2016)

Clinical impact, reactogenicity and immunogenicity after the first CoronaVac dose in dialysis patients: a Phase IV prospective study
por: Medina-Pestana, José, et al.
Publicado: (2021)

Colonization with Escherichia coli ST131-H30R (H30R) Corresponds with Increased Serum Anti-O25 IgG Levels and Decreased TNFα and IL-10 Responsiveness to H30R
por: Johnston, Brian D., et al.
Publicado: (2023)

Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac
por: Nantanee, Rapisa, et al.
Publicado: (2022)

Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study
por: Medina-Pestana, José, et al.
Publicado: (2021)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
por: Rosa Duque, Jaime S., et al.
Publicado: (2022)

Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic Escherichia coli Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies
por: Weerdenburg, Eveline, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

C(60) Bioconjugation with Proteins: Towards a Palette of Carriers for All pH Ranges
por: Di Giosia, Matteo, et al.
Publicado: (2018)

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series
por: Assawasaksakul, Theerada, et al.
Publicado: (2021)

The how’s and what’s of vaccine reactogenicity
por: Hervé, Caroline, et al.
Publicado: (2019)

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
por: Soysal, Ahmet, et al.
Publicado: (2021)

Extraintestinal manifestations of Crohn’s disease
por: Wójcik, Bartosz, et al.
Publicado: (2016)

Extraintestinal Clostridioides difficile infection
por: Hai, Zhao, et al.
Publicado: (2020)

Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial
por: Huu, Tran Ngoc, et al.
Publicado: (2013)

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial
por: Leung, Nancy H L, et al.
Publicado: (2023)

Methods for predicting vaccine immunogenicity and reactogenicity
por: Gonzalez-Dias, Patrícia, et al.
Publicado: (2019)

Bioconjugation and stabilisation of biomolecules in biosensors
por: Liébana, Susana, et al.
Publicado: (2016)

Tyrosine bioconjugation – an emergent alternative
por: Szijj, Peter A., et al.
Publicado: (2020)

Tyrosine bioconjugation with hypervalent iodine
por: Declas, Nina, et al.
Publicado: (2022)

Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
por: Gordeychuk, Ilya V., et al.
Publicado: (2023)

Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children
por: Dicko, Alassane, et al.
Publicado: (2013)

Extraintestinal Manifestations of Inflammatory Bowel Disease
por: Vavricka, Stephan R., et al.
Publicado: (2015)

Autoantibodies in the Extraintestinal Manifestations of Celiac Disease
por: Yu, Xuechen B., et al.
Publicado: (2018)

Extraintestinal Manifestations of Inflammatory Bowel Disease
por: Al-Quorain, Abdulaziz A.
Publicado: (2019)

A rare case of extraintestinal amebiasis
por: Fu, Bao, et al.
Publicado: (2022)

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands
por: Kaaijk, Patricia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gakucv3sce6e66df7l62fagvut